{"groups":[{"description":"1/Phase I:\n\nDrug: Fludarabine\n\nDays -5 to Day -1: Fludarabine 25 mg/m\\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.\n\nOther Names: •Fludara\n\nBiological/Vaccine: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)\n\nDay 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.\n\nDrug: Cyclophosphamide\n\nDays -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.\n\nOther Names: •Cytoxan\n\nDrug: Aldesleukin\n\nAldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).\n\nOther Names: •Proleukin","id":"FG000","title":"Arm A01 Anti-mesothelin CAR PBL 1x10^6 + IL-2"},{"description":"1/Phase I:\n\nDrug: Fludarabine\n\nDays -5 to Day -1: Fludarabine 25 mg/m\\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.\n\nOther Names: •Fludara\n\nBiological/Vaccine: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)\n\nDay 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.\n\nDrug: Cyclophosphamide\n\nDays -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.\n\nOther Names: •Cytoxan\n\nDrug: Aldesleukin\n\nAldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).\n\nOther Names: •Proleukin","id":"FG001","title":"Arm A02 Anti-mesothelin CAR PBL 3x10^6 + IL-2"},{"description":"1/Phase I:\n\nDrug: Fludarabine\n\nDays -5 to Day -1: Fludarabine 25 mg/m\\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.\n\nOther Names: •Fludara\n\nBiological/Vaccine: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)\n\nDay 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.\n\nDrug: Cyclophosphamide\n\nDays -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.\n\nOther Names: •Cytoxan\n\nDrug: Aldesleukin\n\nAldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).\n\nOther Names: •Proleukin","id":"FG002","title":"Arm A03 Anti-mesothelin CAR PBL 1x10^7 + IL-2"},{"description":"1/Phase I:\n\nDrug: Fludarabine\n\nDays -5 to Day -1: Fludarabine 25 mg/m\\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.\n\nOther Names: •Fludara\n\nBiological/Vaccine: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)\n\nDay 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.\n\nDrug: Cyclophosphamide\n\nDays -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.\n\nOther Names: •Cytoxan\n\nDrug: Aldesleukin\n\nAldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).\n\nOther Names: •Proleukin","id":"FG003","title":"Arm A04 Anti-mesothelin CAR PBL 3x10^7 + IL-2"},{"description":"1/Phase I:\n\nDrug: Fludarabine\n\nDays -5 to Day -1: Fludarabine 25 mg/m\\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.\n\nOther Names: •Fludara\n\nBiological/Vaccine: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)\n\nDay 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.\n\nDrug: Cyclophosphamide\n\nDays -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.\n\nOther Names: •Cytoxan\n\nDrug: Aldesleukin\n\nAldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).\n\nOther Names: •Proleukin","id":"FG004","title":"Arm A05 Anti-mesothelin CAR PBL 1x10^8 + IL-2"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"3"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"All reporting groups are in the Phase I portion of the study because the study was terminated before reaching phase II."}